Business Context and Reporting Period
Company: Hyperion DeFi, Inc. (formerly Eyenovia, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: The Company has pivoted to a dual strategy: (1) building a strategic treasury of HYPE digital tokens (native to the Hyperliquid blockchain) to provide shareholder exposure to the ecosystem, and (2) continuing the development and FDA registration of the Optejet ophthalmic liquid delivery device. The Company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $14,720 | $0 |
| Net Loss | $(12,174,452) | $(8,690,919) |
| Net Loss Per Share (Basic & Diluted) | $(4.29) | $(2.50) |
| Cash and Cash Equivalents (Ending) | $7,532,291 | $7,532,291 |
| HYPE Digital Tokens (Fair Value) | $45,500,000 | $45,500,000 |
| Total Assets | $55,659,636 | $55,659,636 |
| Total Liabilities | $18,301,070 | $18,301,070 |
| Stockholders' Equity | $37,358,566 | $37,358,566 |
| Working Capital | $(923,797) | $(923,797) |
| Notes Payable (Gross) | $8,170,886 | $8,170,886 |
Material Changes vs. Prior Period
- Revenue: Revenue is negligible ($14,720 for six months) compared to $27,618 in the prior year period, as the Company has ceased commercial sales efforts for ophthalmic products.
- Net Loss: Net loss decreased to $(12.2) million for the six months ended June 30, 2025, compared to $(22.0) million in the prior year period. This improvement is primarily due to significant reductions in Research and Development (R&D) expenses following the termination of the CHAPERONE study and commercial operations in late 2024.
- Operating Expenses:
- R&D: Decreased 86% to $1.3 million (six months) from $9.0 million, driven by layoffs and the cessation of clinical trials.
- Selling, General & Administrative (SG&A): Increased 36% to $10.1 million (six months) from $7.4 million. This increase is largely attributable to a $5.2 million non-cash stock-based compensation expense related to an executive inducement grant and increased professional fees for strategic evaluation.
- Balance Sheet: Total assets increased significantly from $3.7 million to $55.7 million, driven by the acquisition of $45.5 million in HYPE digital tokens. Stockholders' equity turned positive ($37.4 million) from a deficit of $(13.1) million, resulting from a $50 million private placement of Series A Preferred Stock.
- Cash Flow: Net cash used in operating activities improved to $(7.9) million from $(18.1) million. Net cash provided by financing activities surged to $58.8 million, primarily from the private placement and At-The-Market offerings.
Guidance, Outlook, Risks, and Unusual Items
- Capital Raise & Treasury Strategy: In June 2025, the Company closed a $50 million private placement of Series A Preferred Stock and warrants. Proceeds were used to purchase HYPE tokens. The Company plans to use future capital to further build its HYPE treasury and fund operations.
- Debt Restructuring: The Company amended its Avenue Loan agreement (Fourth Amendment) in June 2025. Key terms include extending maturity to July 2028, reducing the interest rate from 12% to 8% (half cash, half PIK), and eliminating the lender's conversion option. Lender warrants were issued as consideration.
- Going Concern: Management notes substantial doubt about the Company's ability to continue as a going concern for one year due to recurring losses and working capital deficits. Mitigation plans include reducing expenses, raising additional funds, and potentially selling HYPE tokens.
- Nasdaq Compliance: The Company received notice of non-compliance with the Minimum Equity Requirement ($2.5M) based on 2024 year-end equity. However, with equity of $37.4 million as of June 30, 2025, the Company believes it has regained compliance.
- Risks:
- HYPE Volatility: Financial results are now highly correlated with the price of HYPE, which is subject to extreme volatility and regulatory uncertainty.
- Regulatory: Risks include potential classification of HYPE as a security, Investment Company Act implications, and evolving crypto regulations.
- Internal Controls: The Company identified material weaknesses in internal controls regarding the accounting for complex non-routine transactions (licensing, debt modification) and impairment of Right-of-Use assets.
- Unusual Items: A $5.2 million non-cash charge for an executive inducement grant significantly impacted Q2 SG&A. The Company also recorded a $0.1 million gain on debt extinguishment in the first half of 2025.
Investor Verification Checklist
- HYPE Valuation: Verify the fair value methodology for the $45.5 million HYPE holding and monitor price volatility impacts on future earnings.
- Liquidity Runway: Assess the sufficiency of the $7.5 million cash balance against the $0.9 million working capital deficit and ongoing burn rate.
- Debt Covenants: Review the specific terms of the amended Avenue Loan, particularly the interest-only period and PIK interest obligations.
- Internal Controls: Monitor remediation efforts for the disclosed material weaknesses in financial reporting controls.
- Preferred Stock Terms: Review the liquidation preference and dividend accruals (6% annual) on the newly issued Series A Preferred Stock.
- Optejet Progress: Track the timeline for FDA registration of the Optejet device, which remains the only potential source of traditional product revenue.